Video
Dr. Tanya Dorff on latest progress with PARP inhibitors in mCRPC
Author(s):
Video Player is loading.
Tanya Dorff, MD, discusses 3 pivotal trials—PROpel, MAGNITUDE, TALAPRO-2 trial—examining the potential of combining PARP inhibitors with androgen receptor–targeted agents in patients with metastatic castration-resistant prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Related Videos
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Related Content
